COVID-19 Vaccine Developed by Clover Biopharmaceuticals Using Dynavax's CpG 1018 Adjuvant Meets Primary and Secondary Efficacy Endpoints in Global Phase 2/3 TrialPRNewsWire • 09/22/21
Valneva Completes Recruitment of Elderly Participants in Phase 3 Trial of its Inactivated COVID-19 VaccineGlobeNewsWire • 09/14/21
Valneva Receives Notice of Termination of COVID-19 Vaccine Supply Agreement by UK GovernmentGlobeNewsWire • 09/13/21
Dynavax to Present at the H.C. Wainwright 23rd Annual Global Investment ConferencePRNewsWire • 09/09/21
Medigen Vaccine Biologics Announces Launch of Its COVID-19 Vaccine MVC-COV1901 Adjuvanted with Dynavax's CpG 1018 AdjuvantPRNewsWire • 08/23/21
Why COVID Vaccine Stocks Moderna, BioNTech, Novavax, and Dynavax Soared This WeekThe Motley Fool • 08/06/21
Dynavax Technologies Corporation (DVAX) CEO Ryan Spencer on Q2 2021 Results - Earnings Call TranscriptSeeking Alpha • 08/05/21